ScripComing from a fairly large firm – Cubist Pharmaceuticals Inc. – before its $8.4bn acquisition by Merck & Co. Inc. in 2014, Morphic Therapeutic Inc. President and CEO Praveen Tipirneni said he ex
In VivoDevice Transactions Device companies aggregated $2.4 billion in financing for the fourth quarter of 2016, representing an 18% decrease from Q3's $3 billion. Despite the decline, Q4 put up the second-s